Welcome to LookChem.com Sign In|Join Free
  • or
1H-Benzimidazol-5-ylamine, also known as 5-Aminobenzimidazole, is an organic compound with the formula C7H7N3. It is a heterocyclic aromatic amine that features both an imidazole and an aniline functional group. This versatile chemical is widely recognized as a building block in the synthesis of various compounds, including pharmaceuticals, agrochemicals, and dyes. Additionally, it has garnered interest for its potential as an anti-cancer agent. At room temperature, 1H-Benzimidazol-5-ylamine exists as a white to off-white crystalline solid, exhibiting solubility in polar organic solvents such as ethanol and dimethyl sulfoxide, while its solubility in water is limited. Due to its potential to cause skin and eye irritation, it is crucial to handle this chemical with appropriate safety measures.

934-22-5

Post Buying Request

934-22-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

934-22-5 Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazol-5-ylamine is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and reactivity. Its presence in the molecular framework of drugs can contribute to their therapeutic effects, making it an essential component in drug development.
Used in Agrochemical Industry:
In the agrochemical sector, 1H-Benzimidazol-5-ylamine serves as a crucial building block for the creation of pesticides and other agricultural chemicals. Its incorporation into these products can enhance their efficacy in protecting crops from pests and diseases.
Used in Dye Industry:
1H-Benzimidazol-5-ylamine is utilized as a component in the production of dyes, where its aromatic and heterocyclic nature contributes to the color and stability of the final dye products.
Used in Anti-Cancer Research:
1H-Benzimidazol-5-ylamine is studied for its potential as an anti-cancer agent, with ongoing research exploring its ability to target and inhibit the growth of cancer cells. Its unique chemical properties make it a promising candidate for the development of novel therapeutics in oncology.
Used in Chemical Synthesis:
Beyond its applications in specific industries, 1H-Benzimidazol-5-ylamine is a valuable compound in general chemical synthesis, where it can be used to construct a variety of organic molecules with diverse applications in research and industry.

Check Digit Verification of cas no

The CAS Registry Mumber 934-22-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 9,3 and 4 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 934-22:
(5*9)+(4*3)+(3*4)+(2*2)+(1*2)=75
75 % 10 = 5
So 934-22-5 is a valid CAS Registry Number.
InChI:InChI=1/C7H7N3/c8-5-1-2-6-7(3-5)10-4-9-6/h1-4H,8H2,(H,9,10)

934-22-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (725005)  6-Aminobenzimidazole  95%

  • 934-22-5

  • 725005-500MG

  • 726.57CNY

  • Detail

934-22-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 1H-1,3-Benzimidazol-5-amine

1.2 Other means of identification

Product number -
Other names 1H-BENZOIMIDAZOL-5-YLAMINE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:934-22-5 SDS

934-22-5Synthetic route

5-nitrobenzimidazole
94-52-0

5-nitrobenzimidazole

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

Conditions
ConditionsYield
With hydrogen; palladium 10% on activated carbon In methanol under 760.051 Torr; for 20h;100%
With hydrogen; palladium 10% on activated carbon In tetrahydrofuran; ethanol at 20℃; for 4h;92%
With [Co(κS,N-4-(trifluoromethyl)pyrimidine-2-thiolate)3]; methylhydrazine In methanol at 70℃; for 18h; Sealed tube;86%
formic acid
64-18-6

formic acid

benzene-1,2,4-triamine
615-71-4

benzene-1,2,4-triamine

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

Conditions
ConditionsYield
With tetrabutyl-ammonium chloride In water; toluene at 160℃; for 0.166667h; Microwave irradiation;81%
With chloro-trimethyl-silane In water; N,N-dimethyl-formamide at 120℃; for 0.166667h; Microwave irradiation;81%
Behandeln der entstandenen Formylverbindung mit siedender verduennter Schwefelsaeure;
anschliessend Behandeln mit verd.Schwefelsaeue;
formic acid
64-18-6

formic acid

benzene-1,2,4-triyltriamine trihydrochloride

benzene-1,2,4-triyltriamine trihydrochloride

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

Conditions
ConditionsYield
With phosphoric acid; water
4-Nitrophenylene-1,2-diamine
99-56-9

4-Nitrophenylene-1,2-diamine

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: hydrogenchloride / water / 24 h / Reflux
2: palladium on activated charcoal; hydrazine hydrate / ethanol / 4 h / Reflux
View Scheme
benzoimidazole
51-17-2

benzoimidazole

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sulfuric acid; potassium nitrate / 2.08 h / 0 °C
2: tin(II) chloride dihdyrate / ethyl acetate / 12 h / Reflux
View Scheme
1,2-diamino-benzene
95-54-5

1,2-diamino-benzene

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 8 h / Reflux
2: sulfuric acid; potassium nitrate / 2.08 h / 0 °C
3: tin(II) chloride dihdyrate / ethyl acetate / 12 h / Reflux
View Scheme
3,4-dimethoxyphenylisocyanate
37527-66-5

3,4-dimethoxyphenylisocyanate

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

1-(1H-benzo[d]imidazol-5-yl)-3-(3,4-dimethoxyphenyl)urea
1070654-59-9

1-(1H-benzo[d]imidazol-5-yl)-3-(3,4-dimethoxyphenyl)urea

Conditions
ConditionsYield
In tetrahydrofuran for 12h; Heating / reflux;98%
5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

3,4-diethoxy-3-cyclobuten-1,2-dione
5231-87-8

3,4-diethoxy-3-cyclobuten-1,2-dione

3-(1H-benzimidazol-5-ylamino)-4-ethoxycyclobut-3-ene-1,2-dione
922736-19-4

3-(1H-benzimidazol-5-ylamino)-4-ethoxycyclobut-3-ene-1,2-dione

Conditions
ConditionsYield
In ethanol at 75℃; for 20h;97%
trimethylsilyl cyanide
7677-24-9

trimethylsilyl cyanide

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

4-(thiazol-2-yl)-benzaldehyde
198904-53-9

4-(thiazol-2-yl)-benzaldehyde

(1H-benzimidazol-5-ylamino)[4-(1,3-thiazol-2-yl)phenyl]acetonitrile

(1H-benzimidazol-5-ylamino)[4-(1,3-thiazol-2-yl)phenyl]acetonitrile

Conditions
ConditionsYield
Stage #1: 5-aminobenzimidazole; 4-(thiazol-2-yl)-benzaldehyde With acetic acid at 20℃; for 0.333333h;
Stage #2: trimethylsilyl cyanide at 20℃; for 2h;
96%
Stage #1: 5-aminobenzimidazole; 4-(thiazol-2-yl)-benzaldehyde With acetic acid at 20℃; for 0.333333h;
Stage #2: trimethylsilyl cyanide for 2h;
96%
2,4-dichloro-5-bromopyrimidine
36082-50-5

2,4-dichloro-5-bromopyrimidine

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

(1H-Benzoimidazol-5-yl)-(5-bromo-2-chloro-pyrimidin-4-yl)-amine
852357-08-5

(1H-Benzoimidazol-5-yl)-(5-bromo-2-chloro-pyrimidin-4-yl)-amine

Conditions
ConditionsYield
With sodium carbonate In ethanol at 20℃; for 24h;93%
With sodium carbonate In ethanol at 20℃; for 16h;
tert-butyl 2,4-dioxopiperidine-1-carboxylate
845267-78-9

tert-butyl 2,4-dioxopiperidine-1-carboxylate

3,5-dimethoxybenzaldehdye
7311-34-4

3,5-dimethoxybenzaldehdye

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

tert-butyl 11-(3,5-dimethoxyphenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate
1431468-28-8

tert-butyl 11-(3,5-dimethoxyphenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate

Conditions
ConditionsYield
In ethanol at 80℃; for 14h; regioselective reaction;90%
tert-butyl 2,4-dioxopiperidine-1-carboxylate
845267-78-9

tert-butyl 2,4-dioxopiperidine-1-carboxylate

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

3-methoxy-benzaldehyde
591-31-1

3-methoxy-benzaldehyde

tert-butyl 11-(3-methoxyphenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate
1431468-29-9

tert-butyl 11-(3-methoxyphenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate

Conditions
ConditionsYield
In ethanol at 80℃; for 12h; regioselective reaction;90%
tert-butyl 2,4-dioxopiperidine-1-carboxylate
845267-78-9

tert-butyl 2,4-dioxopiperidine-1-carboxylate

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

2-chloro-benzaldehyde
89-98-5

2-chloro-benzaldehyde

tert-butyl 11-(2-chlorophenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate
1431468-26-6

tert-butyl 11-(2-chlorophenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate

Conditions
ConditionsYield
In ethanol at 80℃; for 9h; regioselective reaction;89%
2-bromo-4-fluorobenzaldehyde
59142-68-6

2-bromo-4-fluorobenzaldehyde

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

dimedone
126-81-8

dimedone

3-fluoro-12,12-dimethyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

3-fluoro-12,12-dimethyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 12h; Reflux;89%
5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

dimedone
126-81-8

dimedone

ortho-bromobenzaldehyde
6630-33-7

ortho-bromobenzaldehyde

11-(2-bromophenyl)-8,8-dimethyl-6a,7,8,9,10a,11-hexahydro-1H-imidazo[4,5-a]acridin-10(6H)-one

11-(2-bromophenyl)-8,8-dimethyl-6a,7,8,9,10a,11-hexahydro-1H-imidazo[4,5-a]acridin-10(6H)-one

Conditions
ConditionsYield
In 1,4-dioxane Reflux;87%
5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

1-methyl-6-phenyl-1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid

1-methyl-6-phenyl-1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid

N-(1H-benzo[d]imidazol-5-yl)-1-methyl-6-phenyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide

N-(1H-benzo[d]imidazol-5-yl)-1-methyl-6-phenyl-1H-pyrrolo[3,2-b]pyridine-3-carboxamide

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃;87%
tert-butyl 2,4-dioxopiperidine-1-carboxylate
845267-78-9

tert-butyl 2,4-dioxopiperidine-1-carboxylate

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

4-chlorobenzaldehyde
104-88-1

4-chlorobenzaldehyde

tert-butyl 11-(4-chlorophenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate
1431468-22-2

tert-butyl 11-(4-chlorophenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate

Conditions
ConditionsYield
In ethanol at 80℃; for 12h; regioselective reaction;86%
tert-butyl 2,4-dioxopiperidine-1-carboxylate
845267-78-9

tert-butyl 2,4-dioxopiperidine-1-carboxylate

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

3,4-dichlorobenzaldehyde
6287-38-3

3,4-dichlorobenzaldehyde

11-(3,4-dichlorophenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate
1431468-27-7

11-(3,4-dichlorophenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate

Conditions
ConditionsYield
In ethanol at 80℃; for 10h; regioselective reaction;86%
tert-butyl 2,4-dioxopiperidine-1-carboxylate
845267-78-9

tert-butyl 2,4-dioxopiperidine-1-carboxylate

piperonal
120-57-0

piperonal

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

tert-butyl 11-piperonyl-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate
1431468-30-2

tert-butyl 11-piperonyl-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate

Conditions
ConditionsYield
In ethanol at 80℃; for 15h; regioselective reaction;86%
5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

dimedone
126-81-8

dimedone

ortho-bromobenzaldehyde
6630-33-7

ortho-bromobenzaldehyde

12,12-dimethyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

12,12-dimethyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 15h; Reagent/catalyst; Solvent; Reflux;86%
5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

dimedone
126-81-8

dimedone

2-bromo-5-fluorobenzaldehyde
94569-84-3

2-bromo-5-fluorobenzaldehyde

2-fluoro-12,12-dimethyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

2-fluoro-12,12-dimethyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 12h; Reflux;86%
tert-butyl 2,4-dioxopiperidine-1-carboxylate
845267-78-9

tert-butyl 2,4-dioxopiperidine-1-carboxylate

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

3-Chlorobenzaldehyde
587-04-2

3-Chlorobenzaldehyde

tert-butyl 11-(3-chlorophenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate
1431468-25-5

tert-butyl 11-(3-chlorophenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate

Conditions
ConditionsYield
In ethanol at 80℃; for 13h; regioselective reaction;85%
2-bromo-5-methoxy-benzaldehyde
7507-86-0

2-bromo-5-methoxy-benzaldehyde

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

1,3-cylohexanedione
504-02-9

1,3-cylohexanedione

2-methoxy-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

2-methoxy-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 18h; Reflux;85%
5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

5-chloro-1-methyl-1H-imidazole-2-carbaldehyde
37050-18-3

5-chloro-1-methyl-1H-imidazole-2-carbaldehyde

N-((5-chloro-1-methyl-1H-imidazol-2-yl)methyl)-1H-benzo[d]-imidazol-5-amine

N-((5-chloro-1-methyl-1H-imidazol-2-yl)methyl)-1H-benzo[d]-imidazol-5-amine

Conditions
ConditionsYield
Stage #1: 5-aminobenzimidazole; 5-chloro-1-methyl-1H-imidazole-2-carbaldehyde In methanol at 60℃; for 16h;
Stage #2: With sodium tetrahydroborate In methanol at 0 - 20℃; for 2h;
85%
2-bromo-5-chlorobenzaldehyde
174265-12-4

2-bromo-5-chlorobenzaldehyde

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

dimedone
126-81-8

dimedone

2-chloro-12,12-dimethyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

2-chloro-12,12-dimethyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 12h; Reflux;84%
2-bromo-4-fluorobenzaldehyde
59142-68-6

2-bromo-4-fluorobenzaldehyde

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

1,3-cylohexanedione
504-02-9

1,3-cylohexanedione

3-fluoro-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

3-fluoro-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 14h; Reflux;84%
2-bromothiophene-3-carbaldehyde
1860-99-7

2-bromothiophene-3-carbaldehyde

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

dimedone
126-81-8

dimedone

11,11-dimethyl-11,12-dihydroimidazo[4,5,1-ij]quinolino[4,3,2-de]thieno[3,2-b]quinolin-13(10H)-one

11,11-dimethyl-11,12-dihydroimidazo[4,5,1-ij]quinolino[4,3,2-de]thieno[3,2-b]quinolin-13(10H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 16h; Reflux;84%
tert-butyl 2,4-dioxopiperidine-1-carboxylate
845267-78-9

tert-butyl 2,4-dioxopiperidine-1-carboxylate

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

2,4-dichlorobenzaldeyhde
874-42-0

2,4-dichlorobenzaldeyhde

tert-butyl 11-(2,4-dichlorophenyl)-10-oxo-7,8,10,11-tetrahydro-1H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate
1431468-31-3

tert-butyl 11-(2,4-dichlorophenyl)-10-oxo-7,8,10,11-tetrahydro-1H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate

Conditions
ConditionsYield
In ethanol at 80℃; for 9h; regioselective reaction;83%
5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

1,3-cylohexanedione
504-02-9

1,3-cylohexanedione

ortho-bromobenzaldehyde
6630-33-7

ortho-bromobenzaldehyde

12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 16h; Reflux;83%
2-bromo-5-chlorobenzaldehyde
174265-12-4

2-bromo-5-chlorobenzaldehyde

5-methylcyclohexan-1,3-dione
4341-24-6

5-methylcyclohexan-1,3-dione

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

2-chloro-12-methyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

2-chloro-12-methyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 12h; Reflux;83%
5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

dimedone
126-81-8

dimedone

2-chloro-5-nitrobenzaldehyde
6361-21-3

2-chloro-5-nitrobenzaldehyde

12,12-dimethyl-2-nitro-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

12,12-dimethyl-2-nitro-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 10h; Reflux;83%
tert-butyl 2,4-dioxopiperidine-1-carboxylate
845267-78-9

tert-butyl 2,4-dioxopiperidine-1-carboxylate

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

ortho-anisaldehyde
135-02-4

ortho-anisaldehyde

tert-butyl 11-(2-methoxyphenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate
1431468-32-4

tert-butyl 11-(2-methoxyphenyl)-10-oxo-7,8,10,11-tetrahydro-3H-imidazo[4',5':3,4]benzo[1,2-b][1,6]naphthyridine-9(6H)-carboxylate

Conditions
ConditionsYield
In ethanol at 80℃; for 12h; regioselective reaction;82%
5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

dimedone
126-81-8

dimedone

2-bromo-4-chlorobenzaldehyde
84459-33-6

2-bromo-4-chlorobenzaldehyde

3-chloro-12,12-dimethyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

3-chloro-12,12-dimethyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 12h; Reflux;82%
5-methylcyclohexan-1,3-dione
4341-24-6

5-methylcyclohexan-1,3-dione

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

2-bromo-4-chlorobenzaldehyde
84459-33-6

2-bromo-4-chlorobenzaldehyde

3-chloro-12-methyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

3-chloro-12-methyl-12,13-dihydroimidazo[4,5,1-de]quinolino[4,3,2-mn]acridin-14(11H)-one

Conditions
ConditionsYield
With copper(l) iodide; caesium carbonate; L-proline In 1,4-dioxane for 12h; Reflux;82%
C18H14Cl2N4

C18H14Cl2N4

5-aminobenzimidazole
934-22-5

5-aminobenzimidazole

N4-(2-(1H-indol-3-yl)ethyl)-N2-(1H-benzo[d]imidazol-5-yl)-6-chloroquinazoline-2,4-diamine

N4-(2-(1H-indol-3-yl)ethyl)-N2-(1H-benzo[d]imidazol-5-yl)-6-chloroquinazoline-2,4-diamine

Conditions
ConditionsYield
With hydrogenchloride In ethanol at 120℃; for 6h;82%

934-22-5Relevant academic research and scientific papers

5,5′-Dibenzoimidazole as building block for a new 3D Co(II) coordination polymer: A combined EPR and DFT study using UB3LYP model

Datta, Amitabha,Massera, Chiara,Garribba, Eugenio,Frontera, Antonio

, p. 473 - 479 (2019)

A new Co(II) three-dimensional coordination polymer, [Co(L)(L′)]n (1) [where L = 5,5′-dibenzoimidazole, and L′ = doubly deprotonated terephthalic acid] has been synthesized hydro(solvo)thermally and its molecular and crystal structure have been elucidated through single crystal X-ray diffraction analysis. Each Co(II) ion displays a slightly distorted trigonal bipyramidal geometry, the apical positions being occupied by the nitrogen atoms of two symmetry-related dibenzoimidazole ligands, while the oxygen atoms from three distinct terephthalic acids are in the equatorial plane. Considering the Co2C2O6 dimeric moieties as nodes, and the ancillary ligands as connectors, the structure can be simplified as a 8-c uninodal net of the type bcu, body centered cubic, with point symbol {424·64} and vertex symbol [4·4·4·4·4·4·4·4·4·4·4·4·4(3)·4(3)·4(3)·4(3)·4(3)·4(3)·4(3)·4(3)·4(3)·4(3)·4(3)·4(3)·*·*·*·*]. The EPR spectra for 1 have been reported, showing g|| = 2.176 and g⊥ = 2.052 at RT (room temperature), and g|| = 2.172 and g⊥ = 2.060 at LNT (liquid nitrogen temperature). Finally, the electronic nature of the molecular geometry of 1 has been explored by DFT computation applying the UB3LYP/def2-TZVP level of theory, showing the energy difference between the high spin and low spin configurations.

Industrial Cunninghamia lanceolata carbon supported FeO(OH) nanoparticles-catalyzed hydrogenation of nitroarenes

Fu, Lihua,Li, Dingzhong,Lu, Hao,Qiu, Renhua,Sun, Tulai,Xing, Chen,Yang, Tianbao

, (2022/01/11)

The development of green and efficient methods for hydrogenation of nitroarenes is still highly demanding in organic synthesis. Herein, we report an industrial Cunninghamia lanceolata carbon supported FeO(OH) nanoparticles process for the synthesis of aryl amines with good yields via hydrogenation of nitroarenes. Nine key anti-cancer drug intermediates were successfully achieved with protocol. And Osimertinib intermediate 4m can be smoothly synthesized at a 2.67 kg-scale with >99.5% HPLC purity. This protocol features cheap carbon source, highly catalytic activity, simple operation, kilogram-scalable and recyclable catalysts (eight times without observable losing activity).

Selective Reduction of Nitroarenes to Arylamines by the Cooperative Action of Methylhydrazine and a Tris(N-heterocyclic thioamidate) Cobalt(III) Complex

Ioannou, Dimitris I.,Gioftsidou, Dimitra K.,Tsina, Vasiliki E.,Kallitsakis, Michael G.,Hatzidimitriou, Antonios G.,Terzidis, Michael A.,Angaridis, Panagiotis A.,Lykakis, Ioannis N.

, p. 2895 - 2906 (2021/02/27)

We report an efficient catalytic protocol that chemoselectively reduces nitroarenes to arylamines, by using methylhydrazine as a reducing agent in combination with the easily synthesized and robust catalyst tris(N-heterocyclic thioamidate) Co(III) complex [Co(κS,N-tfmp2S)3], tfmp2S = 4-(trifluoromethyl)-pyrimidine-2-thiolate. A series of arylamines and heterocyclic amines were formed in excellent yields and chemoselectivity. High conversion yields of nitroarenes into the corresponding amines were observed by using polar protic solvents, such as MeOH and iPrOH. Among several hydrogen donors that were examined, methylhydrazine demonstrated the best performance. Preliminary mechanistic investigations, supported by UV-vis and NMR spectroscopy, cyclic voltammetry, and high-resolution mass spectrometry, suggest a cooperative action of methylhydrazine and [Co(κS,N-tfmp2S)3] via a coordination activation pathway that leads to the formation of a reduced cobalt species, responsible for the catalytic transformation. In general, the corresponding N-arylhydroxylamines were identified as the sole intermediates. Nevertheless, the corresponding nitrosoarenes can also be formed as intermediates, which, however, are rapidly transformed into the desired arylamines in the presence of methylhydrazine through a noncatalytic path. On the basis of the observed high chemoselectivity and yields, and the fast and clean reaction processes, the present catalytic system [Co(κS,N-tfmp2S)3]/MeNHNH2 shows promise for the efficient synthesis of aromatic amines that could find various industrial applications.

Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine–hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer

Abdel-Atty, Mona M.,Abouzid, Khaled A. M.,Farag, Nahla A.,Mowafy, Samar,Serya, Rabah A. T.

, p. 1290 - 1312 (2021/07/09)

A series of thieno[2,3-d]pyrimidine-based hydroxamic acid hybrids was designed and synthesised as multitarget anti-cancer agents, through incorporating the pharmacophore of EGFR, VEGFR2 into the inhibitory functionality of HDAC6. Three compounds (12c, 15b and 20b) were promising hits, whereas (12c) exhibited potent VEGFR2 inhibition (IC50=185 nM), potent EGFR inhibition (IC50=1.14 μM), and mild HDAC6 inhibition (23% inhibition). Moreover, compound (15c) was the most potent dual inhibitor among all the synthesised compounds, as it exhibited potent EGFR and VEGFR2 inhibition (IC50=19 nM) and (IC50=5.58 μM), respectively. While compounds (20d) and (7c) displayed nanomolar selective kinase inhibition with EGFR IC50= 68 nM and VEGFR2 IC50= 191 nM, respectively. All of the synthesised compounds were screened in vitro for their cytotoxic effect on 60 human NCI tumour cell lines. Additionally, molecular docking studies and ADMET studies were carried out to gain further insight into their binding mode and predict the pharmacokinetic properties of all the synthesised inhibitors.

Homology modelling, molecular dynamics simulation and docking evaluation of β-tubulin of Schistosoma mansoni

El-Shehabi, Fouad,Mansour, Basem,Bayoumi, Waleed A.,El Bialy, Serry A.,Elmorsy, Mohammad A.,Eisa, Hassan M.,Taman, Amira

, (2021/09/16)

Schistosomiasis is one of the neglected diseases causing considerable morbidity and mortality throughout the world. Microtubules with its main component, tubulin play a vital role in helminthes including schistosomes. Benzimidazoles represent potential drug candidates by binding β-tubulin. The study aimed to generate a homology model for the β-tubulin of S. mansoni using the crystal structure of O vis aries (Sheep) β-tubulin (PDB ID: 3N2G D) as a template, then different β-tubulin models were generated and two previously reported benzimidazole derivatives (NBTP-F and NBTP-OH) were docked to the generated models, the binding results indicated that both S. mansoni, S. haematobium were susceptible to the two NBTP derivatives. Additionally, three mutated versions of S. mansoni β-tubulin wild-type were generated and the mutation (F185Y) seems to slightly enhance the ligand binding. Dynamics simulation experiments showed S. haematobium β-tubulin is highly susceptible to the tested compounds; similar to S. mansoni, moreover, mutated models of S. mansoni β-tubulin altered its NBTPs susceptibility. Moreover, additional seven new benzimidazole derivatives were synthesized and tested by molecular docking on the generated model binding site of S. mansoni β-tubulin and were found to have good interaction inside the pocket.

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I' PATHWAY AND METHODS OF USE THEREOF

-

Page/Page column 56, (2020/03/05)

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE "RIG-I" PATHWAY AND METHODS OF USE THEREOF

-

Paragraph 0440, (2020/03/01)

The present invention is directed to compounds of Formula (I), which are activators of the RIG-I pathway.

Cascade Synthesis of Pyrroles from Nitroarenes with Benign Reductants Using a Heterogeneous Cobalt Catalyst

Ryabchuk, Pavel,Leischner, Thomas,Kreyenschulte, Carsten,Spannenberg, Anke,Junge, Kathrin,Beller, Matthias

supporting information, p. 18679 - 18685 (2020/09/02)

A bifunctional 3d-metal catalyst for the cascade synthesis of diverse pyrroles from nitroarenes is presented. The optimal catalytic system Co/NGr-C@SiO2-L is obtained by pyrolysis of a cobalt-impregnated composite followed by subsequent selective leaching. In the presence of this material, (transfer) hydrogenation of easily available nitroarenes and subsequent Paal–Knorr/Clauson-Kass condensation provides >40 pyrroles in good to high yields using dihydrogen, formic acid, or a CO/H2O mixture (WGSR conditions) as reductant. In addition to the favorable step economy, this straightforward domino process does not require any solvents or external co-catalysts. The general synthetic utility of this methodology was demonstrated on a variety of functionalized substrates including the preparation of biologically active and pharmaceutically relevant compounds, for example, (+)-Isamoltane.

ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR

-

Paragraph 0230; 0240; 0241; 0590; 0592; 0593, (2020/06/16)

Disclosed is a class of new aryl-phosphorus-oxygen compounds as shown in formula (I) as EGFR kinase inhibitors, and pharmaceutically acceptable salts thereof.

Self-Assembled Magnetic Gold Catalysts from Dual-Functional Boron Clusters

Qi, Bin,Wu, Chenchen,Li, Xin,Wang, Dan,Sun, Liang,Chen, Bo,Liu, Wenjing,Zhang, Haibo,Zhou, Xiaohai

, p. 2285 - 2290 (2018/05/15)

A new class of core–shell magnetic gold nanocomposites is prepared in a raspberry-like fashion by the controlled supramolecular host–guest assembly of γ-cyclodextrins (γ-CDs) and boron clusters. In this work, Cs2[closo-B12H12], a fundamental boron cluster, can play a dual role in the preparation of highly monodispersed Au nanoparticles and in the immobilization of Au nanoparticles on the γ-CDs@Fe3O4 surface as an effective anchor. This facile and spontaneous supramolecular strategy allows for the control of the size and composition of the highly stable gold composites. Furthermore, the obtained AuNPs@Fe3O4 composites exhibit an excellent catalytic activity and recyclability for the selective reduction of nitroaromatics to their corresponding aniline compounds, and the fastest reaction can be achieved within 20 s with a high conversion and selectivity at room temperature, which is better than that obtained previously in studies on metal nanoparticle composites as catalysts.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 934-22-5